Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dennis E Hruby

Showing results (71-80 of 85) with videos related to

Pageof 9
Sort By:
Antimicrobial Agents and Chemotherapy|April 25, 2012
Pharmacokinetic comparison of a single oral dose of polymorph form i versus form V capsules of the antiorthopoxvirus compound ST-246 in human volunteersJarasvech Chinsangaram, Kady M Honeychurch, Shanthakumar R Tyavanagimatt, et al.
Plos Pathogens|February 22, 2024
Smallpox lesion characterization in placebo-treated and tecovirimat-treated macaques using traditional and novel methodsTodd M Bell, Paul Facemire, Jeremy J Bearss, et al.
Antimicrobial Agents and Chemotherapy|December 21, 2012
Pharmacokinetic and pharmacodynamic modeling to determine the dose of ST-246 to protect against smallpox in humansJanet M Leeds, Frederique Fenneteau, Nathalie H Gosselin, et al.
Antimicrobial Agents and Chemotherapy|October 9, 2013
Efficacy of tecovirimat (ST-246) in nonhuman primates infected with variola virus (Smallpox)Eric M Mucker, Arthur J Goff, Joshua D Shamblin, et al.
Antiviral Research|March 5, 2011
Evaluation of Lassa antiviral compound ST-193 in a guinea pig modelKathleen A Cashman, Mark A Smith, Nancy A Twenhafel, et al.
Memorias Do Instituto Oswaldo Cruz|July 12, 2023
In vitro susceptibility of eighteen clinical isolates of human monkeypox virus to tecovirimatDesiree Dos Santos Nunes, Luiza M Higa, Régis Linhares Oliveira, et al.
Antimicrobial Agents and Chemotherapy|February 19, 2009
ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justificationRobert Jordan, Arthur Goff, Annie Frimm, et al.
Journal of Virology|January 18, 2008
Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challengeAklile Berhanu, Rebecca L Wilson, Dana L Kirkwood-Watts, et al.
Antimicrobial Agents and Chemotherapy|October 17, 2012
A novel inhibitor of dengue virus replication that targets the capsid proteinChelsea M Byrd, Dongcheng Dai, Douglas W Grosenbach, et al.
Antimicrobial Agents and Chemotherapy|July 11, 2012
Safety and pharmacokinetics of the anti-orthopoxvirus compound ST-246 following a single daily oral dose for 14 days in human volunteersJarasvech Chinsangaram, Kady M Honeychurch, Shanthakumar R Tyavanagimatt, et al.
Pageof 9

Showing results (71-80 of 85) with videos related to

Sort By:
Pageof 9
Antimicrobial Agents and Chemotherapy|April 25, 2012
Pharmacokinetic comparison of a single oral dose of polymorph form i versus form V capsules of the antiorthopoxvirus compound ST-246 in human volunteersJarasvech Chinsangaram, Kady M Honeychurch, Shanthakumar R Tyavanagimatt, et al.
Plos Pathogens|February 22, 2024
Smallpox lesion characterization in placebo-treated and tecovirimat-treated macaques using traditional and novel methodsTodd M Bell, Paul Facemire, Jeremy J Bearss, et al.
Antimicrobial Agents and Chemotherapy|December 21, 2012
Pharmacokinetic and pharmacodynamic modeling to determine the dose of ST-246 to protect against smallpox in humansJanet M Leeds, Frederique Fenneteau, Nathalie H Gosselin, et al.
Antimicrobial Agents and Chemotherapy|October 9, 2013
Efficacy of tecovirimat (ST-246) in nonhuman primates infected with variola virus (Smallpox)Eric M Mucker, Arthur J Goff, Joshua D Shamblin, et al.
Antiviral Research|March 5, 2011
Evaluation of Lassa antiviral compound ST-193 in a guinea pig modelKathleen A Cashman, Mark A Smith, Nancy A Twenhafel, et al.
Memorias Do Instituto Oswaldo Cruz|July 12, 2023
In vitro susceptibility of eighteen clinical isolates of human monkeypox virus to tecovirimatDesiree Dos Santos Nunes, Luiza M Higa, Régis Linhares Oliveira, et al.
Antimicrobial Agents and Chemotherapy|February 19, 2009
ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justificationRobert Jordan, Arthur Goff, Annie Frimm, et al.
Journal of Virology|January 18, 2008
Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challengeAklile Berhanu, Rebecca L Wilson, Dana L Kirkwood-Watts, et al.
Antimicrobial Agents and Chemotherapy|October 17, 2012
A novel inhibitor of dengue virus replication that targets the capsid proteinChelsea M Byrd, Dongcheng Dai, Douglas W Grosenbach, et al.
Antimicrobial Agents and Chemotherapy|July 11, 2012
Safety and pharmacokinetics of the anti-orthopoxvirus compound ST-246 following a single daily oral dose for 14 days in human volunteersJarasvech Chinsangaram, Kady M Honeychurch, Shanthakumar R Tyavanagimatt, et al.
Pageof 9